自从首款嵌合抗原受体T 细胞(chimeric antigen receptor T cell,CAR-T cell)治疗产品被美国食品药品监督管理局(Food and Drug Administration,FDA) 批准上市以来,CAR-T在血液肿瘤领域的临床治疗中取得了可观的成果, 全球的CAR-T 细胞治疗临床...
近日,在 Front Immunol杂志上发表了一篇标题为“Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refrac...
The article delves into the fascinating field of CAR-T cell therapy, which harnesses the power of the immune system to combat cancer. It begins with an exploration of the background science behind cancer immunotherapy, detailing the role of the immune system in cancer surveillanc...
Canine and primate tumor models have been used to further study the safety of CAR T-cells before transitioning to clinical trials. Figure made in BioRender.com. Table 1. Summary of seven preclinical models used in CAR T-cell therapy evaluation for brain tumors. Empty CellModelAdvantages...
西达基奥仑赛获中美双批准的CAR-T疗法,客观缓解率超过89% 西达基奥仑赛注射液(Carvykti，cilta-cel，ciltacabtagene autoleucel)是由传奇生物和强生创新制药联合开发的一款BCMA CAR-T细胞疗法。先后于2024年4月5日，获美国FDA批准，用于治疗复发或难治性多发性骨髓瘤(R/R MM)的成年患者;2024年8月27日获中国...
In the case of B-cell malignancies, CD19 expressed throughout B-cell development, was chosen as an acceptable target even if it’s not a tumor-specific antigen, due to its high expression on most malignant B cells, while at the same time lacking expression on hematopoietic stem cells, limi...
自从首款嵌合抗原受体T 细胞(chimeric antigen receptor T cell,CAR-T cell)治疗产品被美国食品药品监督管理局(Food and Drug Administration,FDA) 批准上市以来,CAR-T在血液肿瘤领域的临床治疗中取得了可观的成果, 全球的CAR-T 细胞治疗临床研究也得到了迅猛发展,尤其是美国和我国,其登记注册的临床研究数量远超其他...
1.Small Study Points to Big Potential of CAR-T Therapies for Autoimmune Diseases | BioSpace 2.CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up | NEJM 3.CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus | NEJM...
今日,顶尖医学期刊《新英格兰医学杂志》(NEJM)发表一项具里程碑意义的研究成果。首批接受CAR-T疗法的15位严重自身免疫疾病患者于中位随访时间为15个月期间,皆持续维持缓解或症状大幅减轻,并已停止所有免疫抑制与抗炎药物的使用。发布于NEJM的评论更称这是项“标志性的发现”。
Chimeric antigen receptor redirected T cells (CAR-T cells) have achieved inspiring outcomes in patients with B cell malignancies, and are now being investigated in other hematologic malignancies and solid tumors. CAR-T cells are generated by the T cells from patients’ or donors’ blood. After ...